StockData
Gain Therapeutics, Inc. logo

Gain Therapeutics, Inc. (GANX) stock

GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.11−0.07 (-5.93%)

Close on Nov 18, 2026Market cap $48.44MP/E –Yield –

Gain Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Gain Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$19.29M. For fiscal 2025 it was -$18.71M. The highest annual figure on record is -$3.48M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$18.71M–
FY2024Dec 31, 2024-$20.35M–
FY2023Dec 31, 2023-$22.25M–
FY2022Dec 31, 2022-$17.78M–
FY2021Dec 31, 2021-$13.83M–
FY2020Dec 31, 2020-$3.48M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$4.68M–
Q1 FY2026Mar 31, 2026-$5.35M–
Q4 FY2025Dec 31, 2025-$4.47M–
Q3 FY2025Sep 30, 2025-$4.79M–
Q2 FY2025Jun 30, 2025-$5.09M–
Q1 FY2025Mar 31, 2025-$4.37M–
Q4 FY2024Dec 31, 2024-$3.33M–
Q3 FY2024Sep 30, 2024-$4.46M–
Q2 FY2024Jun 30, 2024-$8.18M–
Q1 FY2024Mar 31, 2024-$4.38M–
Q4 FY2023Dec 31, 2023-$4.41M–
Q3 FY2023Sep 30, 2023-$4.89M–
Q2 FY2023Jun 30, 2023-$7.73M–
Q1 FY2023Mar 31, 2023-$5.23M–
Q4 FY2022Dec 31, 2022-$4.56M–
Q3 FY2022Sep 30, 2022-$4.75M–
Q2 FY2022Jun 30, 2022-$5.18M–
Q1 FY2022Mar 31, 2022-$3.29M–
Q4 FY2021Dec 31, 2021-$3.21M–
Q3 FY2021Sep 30, 2021-$4.64M–
Q2 FY2021Jun 30, 2021-$3.51M–
Q1 FY2021Mar 31, 2021-$2.47M–
Q4 FY2020Dec 31, 2020-$1.62M–
Q3 FY2020Sep 30, 2020-$819.09K–
Q2 FY2020Jun 30, 2020-$532.47K–
Q1 FY2020Mar 31, 2020-$512.26K–

More Gain Therapeutics figures

See a number that looks wrong?